Citi Maintains Integra Lifesciences(IART.US) With Hold Rating, Cuts Target Price to $28

Citi analyst Joanne Wuensch maintains $Integra Lifesciences(IART.US)$ with a hold rating, and adjusts the target price from $38 to $28.According to TipRanks data, the analyst has a success rate of 62.

Futu NewsMay 23 05:32

Integra Lifesciences(IART.US) Director Buys US$995.82K in Common Stock

$Integra Lifesciences(IART.US)$ Director HILL BARBARA B purchased 36,350 shares of common stock on May 21, 2024 at an average price of $27.3952 for a total value of $995.82K.Source: Announcement What

Futu NewsMay 22 15:50

Integra Lifesciences Holdings Insider Bought Shares Worth $995,816, According to a Recent SEC Filing

Barbara B Hill, Director, on May 21, 2024, executed a purchase for 36,350 shares in Integra Lifesciences Holdings (IART) for $995,816. Following the Form 4 filing with the SEC, Hill has control over a

MT NewswiresMay 22 15:14

Integra LifeSciences Is Maintained at Neutral by Citigroup

Integra LifeSciences Is Maintained at Neutral by Citigroup

Dow JonesMay 22 12:47

Citi: Maintains Integra Lifesciences (IART.US) rating, adjusted from neutral to neutral, and adjusted the target price from $24.00 to $28.00.

Citi: Maintains Integra Lifesciences (IART.US) rating, adjusted from neutral to neutral, and adjusted the target price from $24.00 to $28.00.

Zhitong FinanceMay 22 12:41

Citigroup Maintains Neutral on Integra Lifesciences, Raises Price Target to $28

Citigroup analyst Joanne Wuensch maintains Integra Lifesciences with a Neutral and raises the price target from $24 to $28.

Analyst UpgradesMay 22 12:37